Gene therapy trial for RLBP1-related retinal dystrophy
Part of Eyes & vision clinical trials.
This trial tests an injection (PUMCH-E111) for people with a specific genetic form of inherited retinal dystrophy caused by RLBP1 mutations. It aims to see if the treatment is safe and can help preserve vision.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed RLBP1 gene mutation causing your retinal disease.
- You need to be between 18 and 55 years old.
- The study eye must have some remaining visual field within the central 30 degrees on a specific test.
- You cannot have other eye conditions like glaucoma, uveitis, or recent eye surgery in the study eye.
- You must not have serious health issues like uncontrolled diabetes, heart problems, or bleeding disorders.
- If you are a woman who can get pregnant, you must have a negative pregnancy test and agree to use birth control during and for 12 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an injection called PUMCH-E101 for people with vision loss caused by changes in the RDH12 gene. The goal is to see if it is safe and if it can help improve vision.
This early-stage trial tests a gene therapy aimed at treating inherited retinal dystrophy caused by changes in the RPE65 gene on both copies. It may help slow vision loss or improve eye function, but the study is mainly about safety and learning how the treatment works.
This trial tests a new gene therapy called ZVS203e for people with retinitis pigmentosa caused by a specific RHO gene mutation. It aims to see if the treatment is safe and can help improve vision.
This trial tests a gene therapy for people with a specific genetic form of retinitis pigmentosa (caused by changes in the RPGR gene). It aims to improve vision and slow disease progression.
This early study tests a gene therapy designed for people whose vision problems are caused by an RPGR genetic change. It may help slow or improve the eye disease by treating the underlying cause.
This trial tests an experimental gene therapy (OPGx-RDH12-1001) injected under the retina to treat a rare form of inherited vision loss called LCA caused by RDH12 gene mutations. It aims to see if the treatment is safe and tolerable for people with advanced vision loss.
Hear when a new Inherited Retinal Dystrophy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.